Corvus Pharmaceuticals is progressing Phase 3 trials for soquelitinib in Peripheral T Cell Lymphoma (PTCL) and Phase 1 trials for atopic dermatitis, with interim data expected in December 2024.

Kiora Pharmaceuticals has received regulatory approval to commence the ABACUS-2 Phase 2 clinical trial of KIO-301 for retinitis pigmentosa.

The FDA has extended the PDUFA goal date for Eton Pharmaceuticals' ET-400 New Drug Application to May 28, 2025, requiring additional time to review supplemental information.

Foresee Pharmaceuticals has dosed the first patient in its Phase 2 WINDWARD study evaluating mirivadelgat, a first-in-class oral ALDH2 activator, for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

INmune Bio has concluded patient enrollment for its Phase 2 AD02 trial, targeting early Alzheimer's Disease (AD) patients with elevated neuroinflammation biomarkers.

GSK has agreed to acquire IDRx for $1 billion upfront, plus $150 million in potential milestone payments, to enhance its gastrointestinal cancer portfolio.

Jubilant Therapeutics has dosed the first patients in global clinical trials for JBI-802, a first-in-class CoREST inhibitor, targeting heme-oncology malignancies.

Biofrontera's Ameluz-PDT achieved a 65.5% success rate in complete clearance of sBCC lesions, significantly outperforming placebo at 4.8%.

TNF Pharmaceuticals' isomyosamine demonstrated safety in a 13-week study, supporting longer clinical trials for multiple indications.

Clarity Pharmaceuticals reported increased losses of $23.5 million in the first half, up from $17.2 million in the previous period, impacting stock performance.

Cumberland Pharmaceuticals achieved positive Phase II results for ifetroban in treating cardiac complications of Duchenne muscular dystrophy, marking the first successful study of its kind.

Alebund Pharmaceuticals, a leader in innovative kidney disease treatments, has successfully closed a Pre-C round of financing, raising nearly RMB 200 million. The funds will bolster the company's R&D pipeline, which includes three Class I innovative drugs in various stages of clinical development, with additional products expected to enter clinical testing by 2024.

GSK has agreed to acquire Boston Pharmaceuticals' phase 3-ready liver disease candidate efimosfermin alfa for $1.2 billion upfront, with potential milestone payments bringing the total to $2 billion.

Rhythm Pharmaceuticals has terminated its 2021 licensing agreement with RareStone Group Ltd., reacquiring rights to IMCIVREE (setmelanotide) in mainland China, Hong Kong, and Macau for $6.3 million.

DyDo Pharma has launched FIRDAPSE (amifampridine) in Japan for Lambert-Eaton myasthenic syndrome, marking Catalyst Pharmaceuticals' continued expansion of its rare disease portfolio globally.

Quoin Pharmaceuticals' QRX003 demonstrates significant symptom reduction in a Netherton Syndrome clinical trial, with an 83% improvement observed in the first subject after 12 weeks.

TAHO Pharmaceuticals has commenced a Phase III clinical trial in the U.S. for TAH3311, an oral dissolving film (ODF) formulation of apixaban.

TAHO Pharmaceuticals has begun a Phase III clinical trial in the U.S. for TAH3311, an oral dissolving film (ODF) formulation of apixaban.

A new report provides an overview of the global clinical trial landscape for cerebral palsy, including trial numbers and enrollment trends.

The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.